FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma

NAOYUKI OKABE1, JUNJI EZAKI2, TAKUMI YAMAMURA1, SATOSHI MUTŌ1, JUN OSUGI1, HIROSUMI TAMURA2, JUN-ICHI IMAI2, YUKA YANAGISHIWA3, REIKO HONMA3, MITSUKAZU GOTOH1, SHINYA WATANABE2, SATOSHI WAGURI2 and HIROYUKI SUZUKI1

1Department of Regenerative Surgery and 2Medical-Industrial Translational Research Center, Fukushima Medical University, School of Medicine, Fukushima 960-1295; 3Nippon Gene Co., Ltd., Chiyoda, Tokyo 101-0054, Japan

Received October 20, 2014; Accepted December 10, 2014

DOI: 10.3892/ijo.2015.2817

Abstract. Personalized therapy for non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, has recently been significantly improved by the discovery of various molecular targets. However, this has not been the case for lung squamous cell carcinoma (SCC). In the present study, we identified the family with sequence similarity 83, member B (FAM83B) as a candidate marker for SCC through a comprehensive gene expression analysis and examined its correlations with various clinicopathological factors. The subjects of this study consisted of 215 patients with NSCLC who underwent complete resection from 2005 to 2011 at the Fukushima Medical University Hospital (Fukushima, Japan). They included 102 patients with adenocarcinoma and 113 with SCC. FAM83B expression was first examined in some of the samples by gene expression analysis and western blotting, and then all clinical specimens were evaluated by immunohistochemistry (IHC). The relationship between the quantitative values for IHC and clinicopathological factors was statistically analyzed. The results showed that FAM83B mRNA expression was significantly higher in SCC than in normal lung or adenocarcinoma (P<0.0001). Immunoblot analysis also confirmed this trend. Specimens containing >10% positive area for FAM83B were judged as ‘positive’; 94.3% (107/113) of SCC and 14.7% (15/102) of adenocarcinoma were positive. Patients were divided into two subgroups according to expression (54 high-expression and 53 low-expression patients); the high-expression group was associated with a better disease-free survival (DFS) rate (P=0.042, log-rank test). In conclusion, FAM83B may be a reliable diagnostic and prognostic biomarker for SCC. Detailed analyses of FAM83B function in lung cancer are required to understand how its expression is associated with better prognosis in SCC.

Introduction

Lung cancer is a major cause of cancer-related mortality worldwide, accounting for 18% (1.4 million) of cancer deaths in 2008 (1). It is traditionally classified into two major subtypes, small cell lung cancer and non-small cell lung cancer (NSCLC), the latter of which covers ~85% of newly diagnosed lung cancers, and is further subdivided into two major histological subtypes, adenocarcinoma and squamous cell carcinoma (SCC), which account for ~38 and 20% of all lung cancers, respectively (2). Although historically these histological subtypes did not significantly affect treatment decisions (3), recent advances in NSCLC chemotherapy have introduced treatment options that are subtype-dependent. For example, a folate antimetabolite, pemetrexed, has been used in first-line (4), second-line (5), and maintenance (6) settings for patients with non-SCC. Bevacizumab, an angiogenesis inhibitor, is considered inadequate for SCC because it increases the risk of fatal hemoptysis and is less effective (7,8). In addition, discovery of biomarkers such as recurrent mutations in the epidermal growth factor receptor (EGFR) kinase and a fusion gene of EML4-anaplastic lymphoma kinase has led to a marked change in lung adenocarcinoma treatment (9-12). However, these mutations occur only in adenocarcinoma patients who have never smoked, but are not present in SCC cases that are invariably associated with tobacco smoking (13). In fact, targeted agents developed for lung adenocarcinoma have been largely ineffective against SCC (14), therefore SCC is still treated by conventional platinum-based chemotherapy with little improvement (3).

Recently, some studies have reported several genetic changes related to SCC, such as amplification of TP53, PIK3CA, PDGFR, SOX2, or FGFR1 and mutations in TP53, EGFR, PIK3CA, NRE2L2, PTEN, and DDR2 (15,16). However, they have not been effective in the clinical setting thus far. For this reason, many researchers are exploring driver mutations as well as targeted agents for SCC through gene expression profiling and sequencing studies (16,17). Therefore, we carried out a comprehensive gene expression analysis to identify genes...
that are specifically and highly expressed in lung SCC, and
detected the family with sequence similarity 83, member B (FAM83B) gene. FAM83B has been reported as an important
intermediary in EGFR/RAS signaling, and is highly expressed
at the mRNA level in several cancers, including breast, cervix,
bladder, lung, testis thyroid, and ovary cancer (18). However,
detailed examination of its protein expression and associa-
tion with clinicopathological factors in SCC patients has not
been previously undertaken. Therefore, we conducted western
blotting and immunohistochemical analyses and found that
FAM83B protein was also increased in lung SCC compared
with lung adenocarcinoma or adjacent normal tissues, and
that high-expression levels of FAM83B were associated with
a high disease-free survival (DFS) rate.

Materials and methods

Ethics statement. This study was approved by the Ethics
Committee of Fukushima Medical University (Fukushima,
Japan) (approval no. 1713). Written informed consent
was obtained from all participants involved. We obtained ethics
approval from the Ethics Committees at all Institutions where
samples were analyzed.

Case selection. This study was conducted in a cohort of
patients with NSCLC who underwent pulmonary resection
at Fukushima Medical University Hospital between 2005
and 2011. The tumor samples of 215 patients (SCC 113 cases,
adenoacarcinoma 102 cases) were examined for FAM83B
expression. Tumor samples were selected from patients who
fulfilled all of the following criteria: i) patients suffering from
primary NSCLC with confirmed stage (T1-T3, pN0-pN2, and
PM0); ii) patients who underwent curative surgery but did not
receive any preoperative treatment; and iii) patients whose
clinical follow-up data were available. Follow-up informa-
tion of at least 5 years was available for this study. Use of all
clinical materials was approved by the Institutional Ethics
Committee in Fukushima Medical University. Formalin-fixed,
paraffin-embedded samples from all cases were used for
immunohistochemistry (IHC). For the comprehensive gene
expression analysis, 64 normal lung samples, 60 cases of
adenocarcinoma, and 20 cases of SCC were used. For western
blotting, three normal lung samples, 5 cases of adenocarci-
noma, and 5 cases of SCC were used.

Comprehensive gene expression analysis. A small frac-
tion (7x7 mm) of each surgical specimen was excised and
frozen in liquid nitrogen. Frozen samples were processed for
total RNA extraction using ISOGEN (Nippon Gene Co., Ltd.,
Tokyo, Japan) and for purification of poly(A)+RNA using a
MicroPoly(A)Purist kit (Ambion, Austin, TX, USA). Human
common reference RNA was prepared by mixing equal
amounts of poly(A)+RNA extracted from 22 human cancer
cells lines (A431, A549, AKI, HBL-100, HeLa, HepG2, HL60,
IMR-32, Jurkat, K562, KP4, MKN7, NK-92, Raji, RD, Saos-2,
SK-N-MC, SW-13, T24, U251, U937, and Y79) to reduce cell
type-specific bias in expression (19).

Synthetic polynucleotides (80-mers) representing 31,797
species of human transcripts (MicroDiagnostic, Tokyo,
Japan) were arrayed using a custom arrayer. SuperScript II
(Invitrogen Life Technologies, Carlsbad, CA, USA) and
Cyanine 5-dUTP (Perkin-Elmer, Boston, MA, USA) was used to
synthesize labeled cDNA from 2 µg sample RNA, while
Cyanine 3-dUTP (Perkin-Elmer)-labeled cDNA was synthe-
sized from 2 µg reference RNA. Hybridization was performed
with a Labeling and Hybridization kit (MicroDiagnostic).
Signals were measured with a GenePix 4000B Scanner (Axon
Instruments, Inc., Union city, CA, USA) and then processed
into primary expression ratios (ratio of the cyanine-5 inten-
sity of each sample to the cyanine-3 intensity of the human
common reference RNA). Each ratio was normalized by multi-
plication with the normalization factors using GenePix Pro 3.0
software (Axon Instruments, Inc.). The primary expression
ratios were converted into log2 values (designated log ratios).
We assigned an expression ratio of 1 (log ratio of 0) for spots
that exhibited fluorescence intensities under the detection
limits, and we included these in the signal calculation of the
mean averages. The data were processed using Microsoft
Excel software (Microsoft, Bellevue, WA, USA) and MDI
gene expression analysis software package (MicroDiagnostic).
Data corresponding to FAM83B were extracted, and sta-
tistical analysis of the Kruskal-Wallis test was performed using
GraphPad Prism ver. 6.0 (GraphPad Software, Inc., San Diego,
CA, USA).

Immunoblot analysis. Frozen tissues from tumor and non-tumor
regions were homogenized with RIPA buffer [150 mM sodium
chloride, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), 25 mM Tris-HCl (pH 7.6)] containing
protease inhibitor cocktail (Roche Diagnostics, Indianapolis,
IN, USA) using a glass homogenizer (Wheaton Dounce Tissue
Grinder) on ice. The homogenate were centrifuged
at 10,000 x g at 4°C for 20 min to remove debris, and the
supernatants were mixed with an equal volume of a 20 mM
Tris-HCl (pH 6.8) buffer containing 2% SDS, 12% glucose,
2% 2-mercaptoethanol, 0.002% PBS, and BSB. The proteins
contained in the supernatants were separated by SDS-PAGE
using 5-20% gradient polyacrylamide gels (SuperSep Ace
5-20%; Wako Pure Chemical Industries, Ltd., Osaka, Japan)
according to the Laemmli method (20). Separated proteins
were transferred to polyvinylidene difluoride membranes
(Millipore, Billerica, MA, USA), according to the method of
Towbin et al (21). The membranes were blocked with 5% skim
milk in T-PBS (0.137 M NaCl, 2.6 mM KCl, 1.8 mM
KH2PO4, 8.1 mM Na2HPO4, 12H2O, and 0.005% Tween-20)
and incubated with primary antibodies overnight at 4°C. The
membranes were incubated with anti-FAM83B (1:2,000,
HPA031464; Atlas Antibodies AB, Stockholm, Sweden) or
anti-GAPDH (1:2,500, no. 2118; Cell Signaling Technology,
Inc., Danvers, MA, USA) as primary antibodies, and then
with horseradish peroxidase-conjugated goat anti-rabbit
immunoglobulin G antibody (1:10,000; GE Healthcare Life
Sciences, Tokyo, Japan) as a secondary antibody. The signals
were detected by ImageQuant LAS 4000 using Prime Western
Blotting Detection Reagent (both from GE Healthcare Life
Sciences).

IHC and quantitative analysis. Tissue specimens were fixed
in formalin and embedded in paraffin. Sections were autoclaved
in 0.01 M citrate buffer (pH 6.0) for antigen retrieval. After

1000 OKABE et al: FAM83B EXPRESSION IN LUNG SQUAMOUS CELL CARCINOMA
blocking in 5% skim milk, sections were incubated with a rabbit polyclonal anti-FAM83B antibody (HPA031464; Atlas Antibodies AB) at a dilution of 1:100 at 4°C overnight. They were further incubated for 20 min at room temperature with a
biotinylated goat anti-rabbit IgG (1:400 dilution, Vectastain Elite ABC kit; Vector Laboratories, Inc., Burlingame, CA, USA), and then with avidin-biotin-HRP regent (1:200 dilution; Vectastain Elite ABC kit; Vector Laboratories, Inc.) for 30 min at room temperature. They were observed under a microscope (BX50; Olympus, Tokyo, Japan) and positivity was judged when >10% of the area was occupied with positive cells.

For quantification of staining intensity, tissue sections were immunohistochemically stained without nuclear counter staining. For each specimen, five regions of 680x860 µm each were randomly selected, and the images were captured with a microscope (BX51) equipped with a 20x objective lens (UPlanSApo) and a CCD camera (DP71) (all from Olympus). Images with no tissues sections were also acquired as a background signal. All images were converted to 256-level gray scale images and then inverted using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Mean intensity values were measured only in the tumor regions, from which the background value was subtracted. According to the values, patients were divided into two groups; values with equal or higher than median were classified into a ‘high-expression group’, while those less than the median into a ‘low-expression group’.

**Statistical analysis.** Associations of FAM83B expression levels with clinical characteristics were evaluated using Pearson’s χ² test. DFS and overall survival (OS) in patients with completely resected lung cancers were analyzed. DFS was measured from the time of surgery to initial tumor relapse (local recurrence or distant). OS was calculated from the time of surgery to death at last follow-up date, and 95% confidence interval was evaluated by survival analysis using the Kaplan-Meier method. Survival outcomes for the high- versus the low-expression group were compared using the log-rank test. Statistical significance was set at P<0.05 for all analyses. Multivariate analysis was performed using Cox regression analysis with the following pre-specified variables: gender, pathological stage, smoking, and FAM83B status. All statistical analyses were performed using SPSS version 20.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered statistically significant.

**Results**

**FAM83B expression in lung cancer and normal tissue.** We first extracted the expression ratios of FAM83B from the comprehensive gene expression analysis data, and compared these among 20 cases of SCC, 60 cases of adenocarcinoma, and 64 samples of adjacent normal tissue. As shown in Fig. 1A, FAM83B mRNA levels in SCC were significantly higher than those in adenocarcinoma (P<0.0001) and normal tissues (P<0.0001), but there was no significant difference between levels in adenocarcinoma and normal tissues (Fig. 1A). We next analyzed FAM83B protein expression in five SCC cases, five adenocarcinoma cases, and three normal tissue samples by western blotting. FAM83B protein was detected as a signal with an apparent molecular mass of ~110 kDa. The FAM83B signal intensities in lung cancer were stronger than that in adjacent normal tissue, and the SCC samples expressed FAM83B at higher levels in comparison with the adenocarcinoma samples (Fig. 1B).

**Localization of FAM83B in lung cancer and normal lung tissue.** To evaluate FAM83B expression in paraffin-embedded tissue samples that were retrospectively collected, we attempted immunohistochemical analyses using anti-FAM83B polyclonal antibodies. As shown in Fig. 1C, while the FAM83B signal was only weakly or barely detected in adjacent normal and lung adenocarcinoma tissues, some SCC tissues showed highly intense signals. The staining patterns of FAM83B differed in the same tissue sample as well as among SCC cases; it was often observed along the cell surface and occasionally in the cytoplasm, and in other cells it was localized both in the plasma membranes and cytoplasm (Fig. 1C). When positivity was examined, 94.7% of SCCs (107 out of 113 cases) and 14.7% of adenocarcinoma (15 out of 102 cases) were positive, and overall 56.7% (122 out of 215 cases) of lung cancers were positive. In contrast, all corresponding adjacent normal lung tissues were negative. Thus, sensitivity and specificity were calculated as 94.5 and 85.3%, respectively.

**Relationship between FAM83B and clinicopathological variables of SCC.** The immunoreactivities for FAM83B varied among SCC tissues (Fig. 2A-C). Therefore, to examine the relationship between FAM83B protein levels and clinicopathological factors, FAM83B signal intensities were quantified by image analysis. When 107 FAM83B-positive cases of lung SCC were analyzed, the intensity values for FAM83B were distributed from 3.37 to 63.79 with a median of 17.01 (Fig. 2D). Then, the 107 cases were divided into a high-expression group (54 cases) and a low-expression group (53 cases), and were subjected to an association analysis with clinicopathological factors. Clinicopathological data for SCC patients included in this analysis are summarized in Table I. Notably, the majority of patients were male (88.8%), aged ≥65 years (81.3%), and smokers (Brinkman index ≥600, 86.0%). Percentages of patients with pathologic stage I and II-III were 57.0 and 43.0%, respectively. As a result, a marginal relationship between FAM83B and vascular invasion was found but this was not statistically significant (P=0.066), while there was no significant association between FAM83B protein expression and any of the factors examined including age, gender, smoking history, pT factor, pN factor, p stage, tumor differentiation, pleural invasion, or lymphatic vessel invasion.

**Survival outcomes according to FAM83B expression.** We drew Kaplan-Meier survival estimates for the OS and DFS and compared the two groups using the log-rank test. In the high-expression group, there was a significant extension in the DFS (HR: 0.491, P=0.042; Fig. 2E) while OS did not differ significantly (HR: 0.848, P=0.650; Fig. 2F). We also applied univariate analysis to evaluate associations between DFS and several important clinicopathological factors including age, gender, smoking history, pT factor, pN factor, p stage, tumor differentiation, pleural invasion, lymphatic vessel invasion, vascular invasion, or FAM83B expression by the Cox proportional hazards model. pT factor, pN factor, p stage, pleural invasion, lymphatic vessel invasion, vascular invasion, and low protein expression of FAM83B were significantly associated.
with DFS (Table II). In a multivariate statistical analysis, however, the association did not reach statistical significance (P=0.197) (Table II), indicating that FAM83B expression could not be considered as an independent prognostic factor.

Figure 2. Immunohistochemical quantification of the family with sequence similarity 83 member B (FAM83B) expression and association with clinical outcomes among squamous cell carcinoma (SCC) patients. (A-D) Immunohistochemical images for FAM83B with (A) high, (B) medium, and (C) low intensities. During the imaging process, cancer regions (dotted line) were extracted and their average intensities were measured. (D) Values for 107 SCC clinical samples are shown as a histogram. Patients were divided in FAM83B-high and -low expression groups. Kaplan-Meier curves for (E) disease-free survival (DFS) and (F) overall survival (OS) in the high (blue line) and low (red line) expression groups. Statistical analysis was performed using the log-rank test.
Discussion

It has recently been reported that FAM83B can act as an important intermediary in aberrant EGFR/RAS signaling, and is actually highly expressed in several cancer tissues, such as breast and lung cancer (18). In the present study, we intensively examined the expression of FAM83B in lung cancer at both the mRNA and protein level, and found that it was highly expressed in lung SCC rather than in lung adenocarcinoma or adjacent non-cancer regions. Importantly, higher FAM83B expression evaluated by IHC was associated with longer DFS. Previously, Cipriano et al (18) investigated a microarray data set obtained from Oncomine (https://www.oncomine.org/), and found that FAM83B expression was associated with specific cancer subtypes, increased tumor grade, and decreased OS. In the case of lung cancers, they demonstrated that FAM83B expression was higher in SCC than adenocarcinoma (P=0.00084), and that it was associated with increasing T stage (P=0.016). Therefore, our data support their conclusions by additionally examining FAM83B protein levels, and further provide significant evidence that it is associated with better prognosis of SCC.

Table I. Relationship between FAM83B expression and clinicopathological parameters in SCC.

| Characteristic                  | Total n=107 | FAM83B high n=54 (50.5%) | FAM83B low n=53 (49.5%) | P: high vs. low |
|--------------------------------|-------------|--------------------------|-------------------------|----------------|
| Gender                         |             |                          |                         |                |
| Female                         | 12 (11.2%)  | 7 (58.3%)                | 5 (41.7%)               | 0.563          |
| Male                           | 95 (88.8%)  | 47 (49.5%)               | 48 (50.5%)              |                |
| Age (years)                    |             |                          |                         |                |
| <65                            | 20 (18.7%)  | 7 (35.0%)                | 13 (65.0%)              | 0.125          |
| ≥65                            | 87 (81.3%)  | 47 (54.0%)               | 40 (46.0%)              |                |
| Smoking history (BI)           |             |                          |                         |                |
| <600                           | 15 (14.0%)  | 8 (53.3%)                | 7 (46.7%)               | 0.811          |
| ≥600                           | 92 (86.0%)  | 46 (50.0%)               | 46 (50.0%)              |                |
| pT factor                      |             |                          |                         |                |
| T1                             | 36 (33.6%)  | 22 (61.1%)               | 14 (38.9%)              | 0.117          |
| T2+T3                          | 71 (66.4%)  | 32 (45.1%)               | 39 (54.9%)              |                |
| pN factor                      |             |                          |                         |                |
| N0                             | 76 (71.0%)  | 41 (53.9%)               | 35 (46.1%)              | 0.260          |
| N1+N2                          | 31 (29.0%)  | 13 (41.9%)               | 18 (58.1%)              |                |
| p-TNM stage                    |             |                          |                         |                |
| Stage I                        | 61 (57.0%)  | 33 (54.1%)               | 28 (45.9%)              | 0.387          |
| Stage II/III                   | 46 (43.0%)  | 21 (45.7%)               | 25 (54.3%)              |                |
| Tumor differentiation          |             |                          |                         |                |
| Well/moderate                  | 80 (74.8%)  | 43 (53.8%)               | 37 (46.2%)              | 0.242          |
| Poorly                         | 27 (25.2%)  | 11 (40.7%)               | 16 (59.3%)              |                |
| Pleural invasion               |             |                          |                         |                |
| Positive                       | 34 (31.8%)  | 14 (41.2%)               | 20 (58.8%)              | 0.190          |
| Negative                       | 73 (68.2%)  | 40 (54.8%)               | 33 (45.2%)              |                |
| Lymphatic vessel invasion      |             |                          |                         |                |
| Positive                       | 46 (43.0%)  | 20 (43.5%)               | 26 (56.5%)              | 0.209          |
| Negative                       | 61 (57.0%)  | 34 (55.7%)               | 27 (44.3%)              |                |
| Vascular invasion              |             |                          |                         |                |
| Positive                       | 53 (49.5%)  | 22 (41.5%)               | 31 (58.5%)              | 0.066          |
| Negative                       | 54 (50.5%)  | 32 (59.3%)               | 22 (40.7%)              |                |

FAM83B, family with sequence similarity 83, member B; SCC, squamous cell carcinoma; BI, Brinkman index.
have been proposed as specific for non-SCC. Unfortunately, there is no effective therapy for lung SCC. Therefore, accurate pathological diagnosis, particularly to discriminate non-Scc from Scc in biopsy samples, is an important step in its treatment. However, it has recently been reported that ~20% of hematoxylin-eosin-stained biopsy specimens from NSCLC fail to be appropriately diagnosed, and are known as ‘not otherwise specified’ with poor prognosis (22). Therefore, more effective diagnostic markers for each tissue type of NSCLC are required.

To date, only a few markers for lung SCC have been found, including cytokeratin 5/6 (CK5/6) and p63. CK5/6 is used as a marker of SCC, and its immunohistochemical detection showed 61‑100% sensitivity and 79‑93% specificity for SCC (23,24). p63 is a transcription factor belonging to the p53 family, and has been clinically used as a diagnostic marker (25). However, problems occasionally result because of its low specificity; it also shows positivity in 16‑65% of lung adenocarcinomas (26). Recently, development of specific antibodies against p40 (ΔNp63) together with immunohistochemical evaluation of TTF‑1 and p40 have made it possible to completely discriminate lung adenocarcinoma and SCC (27). Immunohistochemical detection of FAM83B in this study showed 94.5% sensitivity and 85.3% specificity for SCC. This highly accurate result indicates that FAM83B could be a reliable diagnostic marker for lung SCC. Further development of the detection system would be helpful for accurate and rapid diagnosis.

Prognosis of lung SCC is generally worse than that of lung adenocarcinoma (28). It is well known that lung SCC is associated with high smoking rates and complications such as interstitial pneumonia and chronic obstructive pulmonary disease resulting from smoking history, which hampers optimal treatments of chemotherapy, including adjuvant chemotherapy. Therefore, selection of appropriate treatments in so-called ‘personalized therapy’ is more important in determining the treatment strategy for lung SCC, where the information of prognostic biomarkers with higher reliability is helpful. Our data demonstrated that patients with high FAM83B expression tended to exhibit longer DFS (P=0.042), indicating that FAM83B is a candidate biomarker that can predict prognosis of SCC.

At present, we do not know the mechanism by which high expression of FAM83B results in longer DFS. FAM83B protein has an amino-terminal domain of unknown function (DUF1669), which is conserved among FAM83 members and contains a putative phospholipase D‑like motif that is critical for FAM83B‑mediated transformation activity. It has previously been shown that FAM83B can associate with CRAF, p85α and p110α subunits of PI3k, AkT, and EGFR (18,29,30), and is also able to activate phospholipase D via interaction with EGFR (29). These researchers concluded that FAM83B is involved downstream of EGFR, mediating both the MAPk and PI3k/AkT signaling pathways. Consequently, increased expression of FAM83B resulted in the transformation of human mammary epithelial cells (18,29,30). This mechanistic model is consistent with the fact that FAM83B is highly expressed in breast cancer, and that its expression level is associated with its malignancy (18). However, in the case of lung SCC, our

Table II. Cox proportional hazards model analysis of prognostic factors in patients with SCC.

| Variables                  | Hazard ratio (95% CI) | Unfavorable/favorable | P       |
|---------------------------|-----------------------|-----------------------|---------|
| **Univariate analysis**   |                       |                       |         |
| FAM83B                    | 0.489 (0.240‑0.996)   | Weak/strong           | 0.049   |
| Age (years)               | 1.088 (0.449‑2.637)   | ≥65/<65               | 0.852   |
| Gender                    | 1.077 (0.379‑3.063)   | Male/female           | 0.889   |
| pT factor                 | 3.142 (1.293‑7.638)   | T2+T3/T1              | 0.012   |
| pN factor                 | 2.577 (1.288‑5.156)   | N1+N2/N0              | 0.007   |
| p stage                   | 2.309 (1.156‑4.611)   | II+III/I              | 0.018   |
| Pleural invasion          | 4.167 (2.088‑8.316)   | Positive/negative     | 0.0001  |
| Lymphatic vessel invasion | 3.482 (1.703‑7.122)   | Positive/negative     | 0.001   |
| Vascular invasion         | 2.302 (1.131‑4.684)   | Positive/negative     | 0.021   |
| **Multivariate analysis** |                       |                       |         |
| FAM83B                    | 0.610 (0.288‑1.294)   | Weak/strong           | 0.197   |
| Age (years)               | 1.321 (0.519‑3.362)   | ≥65/<65               | 0.559   |
| Gender                    | 1.385 (0.467‑4.108)   | Male/female           | 0.557   |
| pT factor                 | 1.685 (0.557‑5.096)   | T2+T3/T1              | 0.355   |
| pN factor                 | 1.767 (0.577‑5.408)   | N1+N2/N0              | 0.319   |
| p stage                   | 0.960 (0.331‑2.784)   | II+III/I              | 0.94    |
| Pleural invasion          | 2.538 (1.084‑5.944)   | Positive/negative     | 0.032   |
| Lymphatic vessel invasion | 2.453 (1.072‑5.615)   | Positive/negative     | 0.034   |
| Vascular invasion         | 0.955 (0.423‑2.157)   | Positive/negative     | 0.912   |

SCC, squamous cell carcinoma; FAM83B, family with sequence similarity 83, member B.
results indicate that high expression of FAM83B would predict better prognosis. Although it seems contradictory, there has been another example. The transcription factor SOX2 has been identified as an amplified lineage-survival oncogene in lung and esophageal SCC, and its overexpression has been shown to be associated with better prognosis (31-33). The most plausible explanation would be that SOX2 expression might promote squamous differentiation rather than malignant dedifferentiation. FAM83B may also be involved in a similar mechanism, though further studies are required.

Proteome analyses have identified FAM83B as a novel interactor for APC and AXIN-1, both of which are components of a destruction complex of β-catenin and thus regulate the WNT signaling pathway (34). Such additional signaling pathways together with EGFR pathways may be differentially operated in different tissues and during the context of differentiation. Taken together, our findings suggest that although potential FAM83B-targeted therapy might be effective for breast cancer, it would not necessarily be true for lung SCC. More detailed analyses of fundamental signaling pathways using cell lines derived from SCC would give us better conclusions for the function of FAM83B in lung SCC.

Acknowledgements

This research was partially supported by grants for translational research programs from New Energy and Industrial Technology Development Organization (NEDO) (Tokyo, Japan) and Fukushima Prefecture. Dr Y. Yanagisawa and Dr R. Homma are employees of Nippon Gene Co., Ltd. We are extremely grateful to Ms. Y. Kikuta for her technical assistance.

References

1. Jamal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Travis WD: Pathology of lung cancer. Clin Chest Med 32: 669-692, 2011.
3. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
4. Scaglotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
5. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004.
6. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer. N Engl J Med 357: 2542-2550, 2007.
7. Hainsworth JD, Fang L, Huang JE, et al: BRIDGE: a randomised, double-blind, phase 3 study. Lancet 374: 1432-1440, 2009.
8. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550, 2006.
9. Hainsworth JD, Fang L, Huang JE, et al: BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol 6: 109-114, 2011.
10. Turner NC and Seckl MJ: A therapeutic target for smoking-associated lung cancer. Sci Transl Med 2: 62p55, 2010.
11. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007.
12. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
13. Khuder SA: Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 31: 139-148, 2001.
14. Rekhtman N, Paik PK, Arcila ME, et al: Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of the lung: lack of EGFR/ROS1 S1928G and presence of PIK3CA/akt1 mutations. Clin Cancer Res 18: 1167-1176, 2012.
15. Kim HS, Mitsudomi T, Sos RA and Cho BC: Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer 80: 249-255, 2013.
16. Odero Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519-525, 2012.
17. Gold KA, Wistuba II and Kim ES: New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res 18: 3002-3007, 2012.
18. Cipriano R, Graham J, Miskimen KL, et al: FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J Clin Invest 122: 3197-3210, 2012.
19. Miura A, Homma R, Togashi T, et al: Differential responses of normal human coronary artery endothelial cells against multiple cytostatic comparators assessed by gene expression profiles. FEBS Lett 580: 6871-6879, 2006.
20. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
21. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
22. Ou SH and Zell JA: Carcinoma in situ: a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 4: 1202-1211, 2009.
23. Noh S and Shim H: Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: a tissue microarray study of poorly differentiated areas. Lung Cancer 76: 51-55, 2012.
24. Oue R, T ochig i N, Ohori NP and Dacic S: Usefulness of immuno-histochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytotologic specimens. Am J Pathol 136: 81-87, 2011.
25. Conde E, Angulo B, Redondo P, et al: The use of p63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. PLoS One 5: e12209, 2010.
26. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD and Rekhtman N: p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 25: 405-415, 2012.
27. Pelosi G, Fabbri A, Bianchi F, et al: ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 7: 281-290, 2012.
28. Kogure Y, Ando M, Saka H, et al: Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L. J Thorac Oncol 8: 753-758, 2013.
29. Cipriano R, Bryson BL, Miskimen KL, et al: Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B. Oncogene 33: 3306-3316, 2014.
30. Cipriano R, Miskimen KL, Bryson BL, Foy CR, Bartel CA and Jackson MW: FAM83B-mediated activation of PI3K/akt and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies. Oncotarget 4: 729-738, 2013.
31. Bass AJ, Watanabe H, Mermel CH, et al: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242, 2009.
32. Hussenet T, Dali S, Exinger J, et al: SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 5: e8960, 2010.
33. Wilbertz T, Wagner P, Peterken K, et al: SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol 24: 944-953, 2011.
34. Hilger M and Mann M: Triple SILAC to determine stimulus-specific interactions in the Wnt pathway. J Proteome Res 11: 982-994, 2012.